BioNTech SE Sponsored ADR $BNTX Stock: GSK plc Decreases Holdings

GSK plc cut its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 24.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 668,526 shares of the company’s stock after selling 221,298 shares during the period. BioNTech comprises approximately 13.2% of GSK plc’s investment portfolio, making the stock its 4th biggest holding. GSK plc owned approximately 0.26% of BioNTech worth $65,716,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Candriam S.C.A. boosted its stake in shares of BioNTech by 4.7% in the third quarter. Candriam S.C.A. now owns 520,972 shares of the company’s stock worth $51,399,000 after buying an additional 23,442 shares during the last quarter. Pictet Asset Management Holding SA grew its holdings in BioNTech by 11.2% during the third quarter. Pictet Asset Management Holding SA now owns 206,580 shares of the company’s stock worth $20,363,000 after acquiring an additional 20,777 shares during the period. AlphaCentric Advisors LLC raised its position in BioNTech by 4.5% during the third quarter. AlphaCentric Advisors LLC now owns 6,547 shares of the company’s stock valued at $644,000 after acquiring an additional 281 shares in the last quarter. Parallel Advisors LLC raised its position in BioNTech by 50.3% during the third quarter. Parallel Advisors LLC now owns 843 shares of the company’s stock valued at $83,000 after acquiring an additional 282 shares in the last quarter. Finally, Privium Fund Management B.V. lifted its holdings in BioNTech by 6.6% in the third quarter. Privium Fund Management B.V. now owns 32,100 shares of the company’s stock valued at $3,155,000 after acquiring an additional 2,000 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Price Performance

NASDAQ:BNTX opened at $87.65 on Thursday. The stock has a 50 day moving average of $93.80 and a two-hundred day moving average of $96.25. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The firm has a market cap of $22.17 billion, a P/E ratio of -12.80 and a beta of 1.28. The company has a current ratio of 8.55, a quick ratio of 8.52 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on BNTX shares. Argus began coverage on shares of BioNTech in a research note on Thursday, October 8th. They set a “hold” rating on the stock. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. Bank of America reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday, November 4th. HC Wainwright lowered their price target on shares of BioNTech from $130.00 to $110.00 and set a “buy” rating on the stock in a report on Monday. Finally, Berenberg Bank set a $140.00 price objective on shares of BioNTech in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.27.

Insider Transactions at BioNTech

In other news, CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the completion of the sale, the chief executive officer owned 36,209 shares of the company’s stock, valued at $3,453,252.33. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 807,209 shares of company stock worth $79,246,837. Insiders own 19.20% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.